LGALS1 and head and neck cancer: These results are in accordance with previous data demonstrating the therapeutic potential of Gal-1 antibodies in combination with ICIs in head and neck cancer 83, further supporting the notion that Gal-1 inhibition is a promising strategy to potentiate the efficacy of ICIs in patients with various cancer types.